Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
05/2005
05/31/2005US6899723 Transcutaneous photodynamic treatment of targeted cells
05/31/2005CA2267157C Cancer immunotherapy using tumor cells combined with mixed lymphocytes
05/31/2005CA2158275C Taxanes having an amino substituted side-chain
05/26/2005WO2005047333A1 Non-human transgenic mammal for the constant region of the class a human immunoglobulin heavy chain and applications therof
05/26/2005WO2005046748A1 Device and method for attracting diseased cells and foreign substances
05/26/2005WO2005046588A2 Compounds, compositions, and methods
05/26/2005WO2005046358A1 Method of using whole olive and food having activity against helicobacter pylori
05/26/2005WO2005030225A3 Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers
05/26/2005WO2005027951B1 Method for controlling angiogenesis in animals
05/26/2005WO2005021029A3 Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (boris)
05/26/2005WO2005020901A3 Delivery of a therapeutic agent in a formulation for reduced toxicity
05/26/2005WO2005002582A3 Trp-p8 active compounds and therapeutic treatment methods
05/26/2005WO2005000843A3 Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof
05/26/2005WO2005000318B1 Method of inducing apoptosis and inhibiting cardiolipin synthesis
05/26/2005WO2004108664A3 Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing the same
05/26/2005WO2004083392A3 Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells
05/26/2005WO2003084529A3 Low-pressure mercury vapor discharge lamp
05/26/2005US20050113577 Such as hydrochloride salt 3-[5-(4-methanesulfonyl-piperazin-1-yl-methyl)-1H-indol-2-yl]-1H-quinolin-2-one; signal transduction; for treatment of angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, and inflammatory diseases
05/26/2005US20050113451 7-acetamidinyl derivatives
05/26/2005US20050113440 Compounds that modulate PPAR activity and methods for their preparation
05/26/2005US20050113432 Bis(cyanophenyl)methyl-triazole for use in prevention of breast cancer
05/26/2005US20050113426 Polyhydroxylated benzene-containing compounds
05/26/2005US20050113384 Combinations of (a) an atp-competitive inhibitor of c-acl kinase activity with (b) two or more other antineoplastic agents
05/26/2005US20050113378 As inhibitors of the retinoic acid-metabolism, as drugs; breast cancer; psoriasis
05/26/2005US20050113377 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors
05/26/2005US20050113373 medicine to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a histone deactylase (HDAC) in a biological sample
05/26/2005US20050113370 Therapeutic substituted indazole derivatives
05/26/2005US20050113368 eg (+-) Ethyl 3-[4-{3-(3,4-dihydro-2H-benzo[b][1,4]oxazin-4-yl)propylamino}phenyl]-2-ethoxypropanoate; antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic
05/26/2005US20050113352 Platinum complexes containing chemically modified bile acids, having antitumor activity
05/26/2005US20050113349 2-Alpha vitamin D derivatives having substituents
05/26/2005US20050113329 Contacing cell/body fluid with antibody which binds human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide; for inhibiting tumor growth; gene expression inhibition; immunization
05/26/2005US20050113320 Use of calphostin C to treat drug-resistant tumor cells
05/26/2005US20050113316 Process for producing dammarane sapogenins and ginsenosides
05/26/2005US20050113312 2-0-(-d-glucopyranosyl) ascorbic acid, process for its production, and foods and cosmetics containning compositions comprising it
05/26/2005US20050113308 Pentapetide containing a proline amino acid; cytotoxic agent
05/26/2005US20050113299 Protein a compositions and methods of use
05/26/2005US20050112721 Chimeric peptide immunogens
05/26/2005US20050112709 Histone h3methyltransferase polypeptide
05/26/2005US20050112692 Screening peptide library; incubation complexing
05/26/2005US20050112596 APRIL-A novel protein with growth effect
05/26/2005US20050112574 Isolated nucleic acid; angiogenesis inhibitor
05/26/2005US20050112568 Dgks as modifiers of the p53 pathwha and methods of use
05/26/2005US20050112565 Proteases
05/26/2005US20050112563 Sub-sequences of 2'-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H enzyme; diagnostics; antisense therapeutics
05/26/2005US20050112207 Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells
05/26/2005US20050112206 Mixture of drug, aminoacrylate polymer and acid
05/26/2005US20050112187 Nucleic acid that expresses a polypeptide such as a cytokine and a phospholipid, both having cytotoxic activity; synergistic combination; side effect reduction
05/26/2005US20050112134 Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
05/26/2005US20050112126 Anti-VEGF antibodies
05/26/2005US20050112120 Treatment of refractory human tumors with epidermal growth factor receptor antagonists
05/26/2005US20050112117 Molecules and methods for inhibiting shedding of KIM-1
05/26/2005US20050112110 Isolated polynucleotide sequences; controlling neovasculization; cell growth regulators
05/26/2005US20050112062 Anti-idiotypic vascular endothelial growth factor antibodies and their use as medicaments
05/26/2005US20050112061 Use of a VEGF antagonist in combination with radiation therapy
05/26/2005US20050112060 Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination
05/26/2005CA2545756A1 Antibodies against secretoryleukocyte protease inhibitor
05/26/2005CA2545709A1 Methods and compositions for the treatment of b cell lymphomas and other cancers
05/26/2005CA2545558A1 Pyridopyrimidinones
05/26/2005CA2545454A1 Adenocarcinoma specific antibody sam-6, and uses thereof
05/26/2005CA2545423A1 Combinations for the treatment of proliferative diseases
05/26/2005CA2545364A1 Methods of modulating angiogenesis and cancer cell proliferation
05/26/2005CA2545060A1 Methods of use of thrombin receptor antagonists
05/26/2005CA2545055A1 Macrocyclic kinase inhibitors
05/26/2005CA2544923A1 Method and antisense compound for potentiating anti-cancer agents
05/26/2005CA2544550A1 Use of thienopyrimidines
05/26/2005CA2544252A1 Stem cell culture medium and method of using said medium and the cells
05/26/2005CA2544186A1 Inhibition of fgfr3 and treatment of multiple myeloma with benzimidazole quinolinones
05/26/2005CA2543982A1 Antibodies that bind interleukin-4 receptor
05/26/2005CA2543163A1 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
05/26/2005CA2527904A1 Lactoferrin as an adjuvant in cancer vaccines
05/25/2005EP1533374A1 Novel peptides having camp producing activity
05/25/2005EP1533304A1 Amide derivative
05/25/2005EP1533294A1 Beta-alanine derivative and use thereof
05/25/2005EP1532434A1 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
05/25/2005EP1532251A1 Human acid sensing ion channel 2b (hasic2b), process for producing the same, and its use
05/25/2005EP1532242A2 Methods for preparing purified prostaglandin e synthase
05/25/2005EP1532238A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/25/2005EP1532174A2 Anti-igf-i receptor antibody
05/25/2005EP1532161A2 Vectors for expression of hml-2 polypeptides
05/25/2005EP1532157A2 Novel phosphonic acid based prodrugs of pmea and its analogues
05/25/2005EP1532154A1 Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
05/25/2005EP1532139A1 Total synthesis of myriaporones
05/25/2005EP1532138A1 Inhibitors of tyrosine kinases
05/25/2005EP1532135A1 Nf-kb inhibitors
05/25/2005EP1532133A1 Nf-:b inhibitors
05/25/2005EP1532117A1 Multi-substituded imidazolines and method of use thereof
05/25/2005EP1532111A1 2,5-disubstituted 3-mercaptopentanoic acid
05/25/2005EP1532108A2 Structural carotenoid analogs for the inhibition and amelioration of disease
05/25/2005EP1532105A1 Anthranyl derivatives having an anticholecystokinin activity (anti-cck-1), a process for their preparation, and pharmaceutical use thereof
05/25/2005EP1531907A1 Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer
05/25/2005EP1531879A1 Use of organic compounds
05/25/2005EP1531869A2 Compositions and methods for treating cancer using maytansinoid cd44 antibody immunoconjugates and chemotherapeutic agents
05/25/2005EP1531868A2 Therapeutic agent-containing polymeric nanoarticles
05/25/2005EP1531863A2 Antibody-avidin fusion proteins as cytotoxic drugs
05/25/2005EP1531857A1 Metalloproteinase inhibitors
05/25/2005EP1531851A2 Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use
05/25/2005EP1531850A2 Use of il-21 in cancer and other therapeutic applications
05/25/2005EP1531848A2 Gene differentially expressed in breast and bladder cancer and encoded polypeptides
05/25/2005EP1531847A2 Pharmaceutical formulation
05/25/2005EP1531843A1 Method for treating cervical cancer
1 ... 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 ... 2211